---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091220"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:18:00.956020+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences Q2 2024 net loss $59.0M; cash $389.9M; trial enrollment on track for 2025 readouts

## Summary
- Cash, cash equivalents and marketable securities $389.9M as of June 30, 2024; expected to fund operations into 2027.
- Net loss $59.0M for Q2 2024, compared to $44.1M in Q2 2023; R&D expenses $54.3M.
- Enrollment in SUMMIT, PEAK, APEX registration-directed trials on track; topline results expected from all three in 2025.
- Appointed Cole Pinnow as Chief Commercial Officer; initiated IND-enabling studies for CNS-penetrant ErbB2 program.
- Plan to initiate Phase 1 trial for FGFR2 inhibitor in H2 2024; IND-enabling studies for PI3Ka program ongoing.

## SEC filing metadata
- accession: 0000950170-24-091220
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017024091220/0000950170-24-091220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017024091220/cogt-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091220
- JSON: https://secwatch.observer/filing/0000950170-24-091220.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.